ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Case Report: A Patient on Apremilast Develops Streptococcus Salivarius

Stephanie Kydd Dondero, DO, & Barry Waters, MD  |  October 18, 2019

Apremilast was first marketed in March 2014 for the treatment of adults with psoriatic arthritis (PsA). An immuno­modulating drug, which is a small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine mono­phosphate (cAMP), apremilast is administered orally. By inhibiting PDE4, intracellular cAMP levels are increased. Although the exact mechanism of action is not…

Filed under:Conditions Tagged with:apremilastcase reportimmunosuppressive drugsStreptococcus salivarius

Case Report: Cardiac Tamponade in a Rheumatoid Arthritis Patient

Case Report: Cardiac Tamponade in a Rheumatoid Arthritis Patient

Sirajum Munira, MD, Mamta Sherchan, MD, & Christopher Collins, MD, FACR  |  October 18, 2019

Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease. Although RA develops its central pathology within the synovium of diarthrodial joints, many non-articular organs can be involved, particularly in patients with severe joint disease.1 Although most patients are asymptomatic, cardiac involvement is relatively common and includes rheumatic heart nodules, pericarditis (30–50%), pericardial effusion and…

Filed under:ConditionsRheumatoid Arthritis Tagged with:cardiac tamponadecase reportFellows

Using RISE Data in Research

Elizabeth Hofheinz, MPH, MEd  |  October 17, 2019

The ACR’s RISE registry offers answers on real-world experience to researchers.

Filed under:Meeting ReportsQuality Assurance/ImprovementResearch Rheum Tagged with:2019 ACR/ARP Annual MeetingResearchRISE

Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

Mary Choy, PharmD, BCGP, FASHP  |  October 14, 2019

Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:GoutGout Resource Center

Mortality from Anti-neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Falling Slightly

Will Boggs, MD  |  October 9, 2019

NEW YORK (Reuters Health)—Mortality rates in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) decreased from 1999 to 2017, according to records from the Centers for Disease Control and Prevention (CDC). “The mortality attributed to several rare diseases [e.g., hypersensitivity pneumonitis] has increased in recent years,” Alexander W. Steinberg, MD, from Saint Joseph Hospital, Denver, tells…

Filed under:ConditionsVasculitis Tagged with:AAVGPAmortalitymortality rate

Transbronchial Lung Cryobiopsy a Valid Diagnostic Option in Interstitial Lung Disease

Reuters Staff  |  October 7, 2019

NEW YORK (Reuters Health)—Transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB) had a high level of agreement for diagnosing interstitial lung disease in the first comparative study. “These data suggest that TBLC, when done by an experienced proceduralist, is a valid first-line minimally invasive diagnostic tool for patients with interstitial lung disease deemed to…

Filed under:Conditions Tagged with:biopsyInterstitial Lung Diseaselungtransbronchial lung cryobiopsy (TBLC)

Lupus Flares Pose Greatest Risk for Adverse Pregnancy Outcomes in Women with SLE

Lara C. Pullen, PhD  |  October 7, 2019

According to new research, women with SLE are at the highest risk for adverse pregnancy outcomes during a lupus flare. The data may enable clinicians to use risk stratification and tailored monitoring to counsel SLE patients who are pregnant or considering pregnancy. Researchers also found that maternal age, lupus nephritis and antiphospholipid antibodies may affect pregnancy outcomes…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:flareFlaresLupusOutcomespregnancypregnancy complicationspregnant womenWomen

Nintedanib Slows Lung Deterioration in General Fibrosing Interstitial Lung Disease

Reuters Staff  |  October 2, 2019

NEW YORK (Reuters Health)—Nintedanib dramatically slows lung deterioration in patients with progressive fibrosing interstitial lung diseases, according to a new randomized study.1 Nintedanib has already been shown to be effective against idiopathic pulmonary fibrosis (IPF). The new trial, funded by the manufacturer, Boehringer Ingelheim, and presented t the European Respiratory Society International Congress 2019 in…

Filed under:Drug Updates Tagged with:ILDInterstitial Lung Diseaselung diseaselungsnintedanib

Abx464 Enters Phase 2 Clinical Trials for RA in Europe

Michele B. Kaufman, PharmD, BCGP  |  September 30, 2019

In Europe, researchers are evaluating the safety, tolerability and efficacy of ABX464 in rheumatoid arthritis patients…

Filed under:Drug Updates Tagged with:ABX464EuropeRheumatoid Arthritis (RA)

Chu KyungMin / shutterstock.com

The Bath Ankylosing Spondylitis Functional Index’s History & Patient View

Jason Liebowitz, MD, FACR  |  September 26, 2019

Sir William Osler, widely regarded as one of the greatest physicians of the 20th century, once said, “He who studies medicine without books sails an uncharted sea, but he who studies medicine without patients does not go to sea at all.”1 This sentiment is particularly true in the field of rheumatology, in which understanding the…

Filed under:Axial SpondyloarthritisConditionsPatient Perspective Tagged with:Ankylosing SpondylitisBath Ankylosing Spondylitis Disease Activity Index (BASDAI)Bath Ankylosing Spondylitis Functional Index (BASFI)Disease Activity Score (DAS)

  • « Previous Page
  • 1
  • …
  • 120
  • 121
  • 122
  • 123
  • 124
  • …
  • 330
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences